Determination of hypericin and hyperforin content in different phytopharmaceuticals and dietary supplements containing Hypericum perforatum extract

Salud Mental

Volumn 26, Issue 4, 2003, Pages 59-63

  Tortoriello, Jaime ^a   Zamilpa, Alejandro ^a   Herrera, Armando ^a   Romero Cerecero, Ofelia ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Antidepressant; Complementary medicine; Dietary supplement; Hyperforin; Hypericin; Hypericum perforatum; Phytopharmaceutical

Indexed keywords

HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT;

ARTICLE; DEPRESSION; DIET SUPPLEMENTATION; DRUG CAPSULE; DRUG INDICATION; HERBAL MEDICINE; MEXICO; TABLET; WOUND HEALING;

EID: 0142059849     PISSN: 01853325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BARNES J, ANDERSON LA, PHILLIPSON JD: St. John's wort (Hypericum perforatum L): A review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol, 53:583-600, 2001.
2. BIBER A, FISCHER H, RÖMER A, CHATERJEE SS: Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers. Pharmacopsychiatry, 31 (Supl. 1):36-43, 1998.
3. BILIA AR, BERGONZI MC, MORGENNI F, MAZZI G, VINCIERI FF: Evaluation of chemical stability of St. John's wort commercial extract and some preparations. Int J Pharm, 213:199-208, 2001.
4. BUTTERWECK V, WALL A, LIEFLÄNDER-WULF U, WINTERHOFF H, NAHRSTEDT A: Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry, 30 (Supl. 2):117-124, 1997.
5. CHATTERJEE SS, KOCH E, NÖLDNER M, BIBER A, ERDELMEIER C: Hyperforin and hypericum extract: Interactions with some neurotransmitter systems. Phytomedicine, 3(Supl. 1):106, 1996.
6. CHATTERJEE SS, NÖLDNER M, KOCH E, ERDELMEIER C: Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry, 31(Supl. 1):7-15, 1998.
7. ERDELMEIER CA: Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry, 31(Supl. 1):2-6, 1998.
8. ERNST E: St. John's wort, an antidepressant? A systematic, criteria based review. Phytomedicine, 2:67-71, 1995.
9. GAEDCKE F: Johanniskraut und dessen Zubereitungen. Deutsche Apotheker Zeitung, 137:3753-3757, 1997.
10. GREESON JM, SANFORD B, MONTI DA: St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological and clinical literature. Psychopharmacology, 153:402-414, 2001.
11. HARRER G, HÜBNER WD, PODZUWEIT H: Effectiveness and tolerance of the hypericum extract L1 160 compared to maprotiline: a multicenter, double-blind study. J Geriatr Psychiatry Neurol, 7(supl. 1):24-28, 1994.
12. HÜBNER WD, KIRSTE T: Experience with St. John's wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res, 15:367-370, 2001.
13. JUDD LL: Mood disorders in the general population represent an important and worldwide public health problem. Int Clin Psychopharmacol, 10(Supl 4):5-10, 1995.
14. KASPER S: Hypericum perforatum - A review of clinical studies. Pharmacopsychiatry, 34(Supl. 1):51-55, 2001.
15. KÄUFELER R, MEIER B, BRATTSTRÖM A: Efficacy and tolerability, of Ze 117 St. John's wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10. An overview. Pharmacopsychiatry, 34 (Supl. 1):49-50, 2001.
16. KERB R, BROCKMÖLLER J, STAFFELDT B, PLOCH M, ROOTS I: Single dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother, 40:2087-2093, 1996.
17. LAAKMANN G, SCHÜLE C, BAGHAI T, KIESER M: St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry, 31 (Supl. 1):54-59, 1998.
18. Ley General de Salud. Reglamento de Insumos para la Salud. Ed. Porrua, México, 2000.
19. MÜLLER WE: St. John's wort (Hypericum), story goes on. Pharmacopsychiatry, 31(Supl. 1):1, 1998.
20. MÜLLER WE, SINGER A, WONNEMANN M, HAFNER U, ROLLI M, SCHÄFER C: Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry, 31 (Supl. 1):16-21, 1998.
21. NATHAN PJ: Hypericum perforatum (St John's wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychocopharmacol, 15:47-54, 2001.
22. POWDER ED: St. John's wort extract. Pharmacopeial Forum, 26:464, 2000.
23. TORTORIELLO J: Neurophytopharmaceuticals: A review; En: Lozoya X, Gomez E, Brunner M (eds.) Simposium IMSS-Farmasa Schwabe, México, 77-98, 1999.
24. WERTH W: Psychotonin M versus imipramin in der chirurgie. Der Kassenarzt, 15:64-68, 1989.
25. WHEATLEY D: LI 160, an extract of St John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry, 30(Supl. 2):77-80, 1997.